← Back to headlines
Wells Fargo Rates BioMarin Pharmaceutical Inc. (BMRN) Overweight Despite Study Discontinuations
Wells Fargo has given BioMarin Pharmaceutical Inc. (BMRN) an "Overweight" rating, despite the discontinuation of its Voxzogo Phase 2 study.
30 Mar, 11:10 — 30 Mar, 11:10
Sources
Showing 1 of 1 sources
